Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
Accelerate bioengineering tools & technologies via academic-industry partnerships to address biomedical problems & enhance medical practice.
Funder: National Institutes of Health
Due Dates: May 28, 2025 (New/Renewal/Resubmission/Revision) | September 7, 2025 (AIDS) | January 27, 2026 | May 7, 2026 (AIDS) | May 27, 2026 | September 7, 2026 (AIDS) | January 27, 2027 | May 7, 2027 (AIDS) | May 27, 2027 | September 7, 2027 (AIDS)
Funding Amounts: No budget cap; budgets must reflect actual project needs. Maximum project period: 5 years.
Summary: Supports academic-industry partnerships to accelerate development and adoption of bioengineering tools and technologies addressing unmet biomedical needs.
Key Information: An academic-industrial partnership is required; applications without this will not be reviewed.
Description
This opportunity from the National Institutes of Health (NIH) supports research partnerships between academic and industrial investigators to accelerate the development and adoption of innovative bioengineering tools and technologies that address significant biomedical problems. The program aims to establish robust, well-characterized solutions that fulfill unmet needs and can enhance understanding of life science processes or improve medical practice. Multidisciplinary teams are expected to apply integrative, quantitative bioengineering approaches, with the goal of delivering practical, impactful technologies within 5–10 years.
Projects may span the spectrum from technology development and validation in research settings to translation into clinical environments, but cannot support commercial production or late-stage (Phase II/III) clinical trials. The required academic-industry partnership is central to the program, ensuring that both sectors contribute substantively to the intellectual and technical aspects of the project.
